Method and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
AssigneeCenter Laboratories, Inc.
InventorsHuai-Cheng Lee, Guang-Tzuu Shane, Hsi-Chieh Wang, Rong Jin Lin
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor. The method comprises administering a composition comprising an effective amount of verapamil and a pharmaceutically acceptable excipient to a subject, wherein the verapamil is capable of binding to at least one of a receptor selected from the group consisting of orexin receptor 1, orexin receptor 2, somatostatin receptor 2 and dopamine D2L receptor of the subject.
Claims16
A use of verapamil for the manufacture of a medicament for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L, receptor, wherein the verapamil is capable of binding to any of the orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L, receptor.
A method of in vitro binding of verapamil with at least one of orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor in a cell, comprising the step of administering an effective amount of verapamil to the cell, wherein the verapamil is any of (R)-(+)-verapamil, (S)-(−)-verapamil, a mixture of (R)-(+)-verapamil and (S)-(−)-verapamil, a pharmaceutically acceptable derivative, stereoisomer, metabolite, salt or solvate thereof, or a combination thereof.
A method of treating a subject having a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor, comprising administering an effective amount of verapamil to the subject.
Use of verapamil as an agonist of somatostatin receptor 2.
Use of verapamil as an antagonist of orexin receptor 1, orexin receptor 2 or dopamine D2L receptor.
Dependencies are inferred from the claim text.